

Regulatory Impact Assessment screening – Consultation on proposals to amend to the terms of service for chemists as set out in Schedule 2 to the Pharmaceutical Services Regulations (Northern Ireland) 1997

Regulatory	Screening Questions	Response to Screening Questions		Full Impact Assessment Required		Justification / Key issues and groups to focus on
		Yes	No	Yes	No	
		Is the policy or amendment to the policy likely to have a direct or indirect impact on businesses?		X		X

	Is the policy or amendment to the policy likely to have a direct or indirect impact on the voluntary / community sector? ¹		X		X	The policy proposals relate to possible amendments to the terms of service for chemists as set out in Schedule 2 to the Pharmaceutical Services Regulations (Northern Ireland) 1997 and will directly impact chemists and pharmacy contractors providing HSC pharmaceutical services. The policy proposals are not likely to have a direct or indirect impact on the voluntary / community sector.
CONCLUSION					X	The Department is of the view that a full Regulatory Impact Assessment is not needed at this time. This will be reviewed and is subject to the results and feedback received as part of this consultation exercise. Further work, including the reconsideration for the need of a full regulatory impact on the policy proposals will be determined at the end of the consultation period.

When Is a Regulatory Impact Assessment Required?

If the answer to any of the above questions is yes, consideration should be given to undertaking a Regulatory Impact Assessment. However, the level of appraisal should be proportionate to the costs involved.

A Regulatory Impact Assessment is not required for:

- i. Proposals which impose **no costs or no savings**, or negligible costs or savings on business, charities, social economy enterprises or the voluntary sector;
- ii. Increases in statutory fees by a predetermined formula such as the rate of inflation; or Road closure orders.

¹ NOTES:

This Includes charities and the social economy sector.

	Position/Job Title	Date
Screened by:		
Eddie Murphy	Acting Head of Medicines Legislation Unit (G7)	25/6/2026
Approved by:		
Chris Garland	Senior Principal Pharmaceutical Officer (G6)	25/06/2026